210 related articles for article (PubMed ID: 29105665)
21. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
22. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.
Anand A; Charney DS; Oren DA; Berman RM; Hu XS; Cappiello A; Krystal JH
Arch Gen Psychiatry; 2000 Mar; 57(3):270-6. PubMed ID: 10711913
[TBL] [Abstract][Full Text] [Related]
23. Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans.
Thiebes S; Leicht G; Curic S; Steinmann S; Polomac N; Andreou C; Eichler I; Eichler L; Zöllner C; Gallinat J; Hanganu-Opatz I; Mulert C
J Psychiatry Neurosci; 2017 Jun; 42(4):273-283. PubMed ID: 28556775
[TBL] [Abstract][Full Text] [Related]
24. Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study.
Abel KM; Allin MP; Kucharska-Pietura K; David A; Andrew C; Williams S; Brammer MJ; Phillips ML
Neuroreport; 2003 Mar; 14(3):387-91. PubMed ID: 12634489
[TBL] [Abstract][Full Text] [Related]
25. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans.
Vollenweider FX; Vontobel P; Oye I; Hell D; Leenders KL
J Psychiatr Res; 2000; 34(1):35-43. PubMed ID: 10696831
[TBL] [Abstract][Full Text] [Related]
26. General and emotion-specific neural effects of ketamine during emotional memory formation.
Becker B; Steffens M; Zhao Z; Kendrick KM; Neumann C; Weber B; Schultz J; Mehta MA; Ettinger U; Hurlemann R
Neuroimage; 2017 Apr; 150():308-317. PubMed ID: 28232170
[TBL] [Abstract][Full Text] [Related]
27. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.
Newcomer JW; Farber NB; Jevtovic-Todorovic V; Selke G; Melson AK; Hershey T; Craft S; Olney JW
Neuropsychopharmacology; 1999 Feb; 20(2):106-18. PubMed ID: 9885791
[TBL] [Abstract][Full Text] [Related]
28. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers.
Adler CM; Goldberg TE; Malhotra AK; Pickar D; Breier A
Biol Psychiatry; 1998 Jun; 43(11):811-6. PubMed ID: 9611670
[TBL] [Abstract][Full Text] [Related]
29. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia.
Holcomb HH; Lahti AC; Medoff DR; Cullen T; Tamminga CA
Neuropsychopharmacology; 2005 Dec; 30(12):2275-82. PubMed ID: 16034443
[TBL] [Abstract][Full Text] [Related]
30. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.
Malhotra AK; Pinals DA; Weingartner H; Sirocco K; Missar CD; Pickar D; Breier A
Neuropsychopharmacology; 1996 May; 14(5):301-7. PubMed ID: 8703299
[TBL] [Abstract][Full Text] [Related]
31. Brain NMDA Receptors in Schizophrenia and Depression.
Adell A
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32585886
[TBL] [Abstract][Full Text] [Related]
32. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
Krystal JH; Abi-Saab W; Perry E; D'Souza DC; Liu N; Gueorguieva R; McDougall L; Hunsberger T; Belger A; Levine L; Breier A
Psychopharmacology (Berl); 2005 Apr; 179(1):303-9. PubMed ID: 15309376
[TBL] [Abstract][Full Text] [Related]
33. Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study.
Stone JM; Erlandsson K; Arstad E; Squassante L; Teneggi V; Bressan RA; Krystal JH; Ell PJ; Pilowsky LS
Psychopharmacology (Berl); 2008 Apr; 197(3):401-8. PubMed ID: 18176855
[TBL] [Abstract][Full Text] [Related]
34. Modulatory effects of ketamine, risperidone and lamotrigine on resting brain perfusion in healthy human subjects.
Shcherbinin S; Doyle O; Zelaya FO; de Simoni S; Mehta MA; Schwarz AJ
Psychopharmacology (Berl); 2015 Nov; 232(21-22):4191-204. PubMed ID: 26223493
[TBL] [Abstract][Full Text] [Related]
35. [Effects of a subanaesthetic dose of ketamine on emotional and behavioral state in healthy subjects].
Micallef J; Tardieu S; Gentile S; Fakra E; Jouve E; Sambuc R; Blin O
Neurophysiol Clin; 2003 Jun; 33(3):138-47. PubMed ID: 12909392
[TBL] [Abstract][Full Text] [Related]
36. A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects.
Yurgelun-Todd DA; Renshaw PF; Goldsmith P; Uz T; Macek TA
Psychopharmacology (Berl); 2020 Feb; 237(2):317-328. PubMed ID: 31773211
[TBL] [Abstract][Full Text] [Related]
37. Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study.
Windischberger C; Lanzenberger R; Holik A; Spindelegger C; Stein P; Moser U; Gerstl F; Fink M; Moser E; Kasper S
Neuroimage; 2010 Jan; 49(2):1161-70. PubMed ID: 19833214
[TBL] [Abstract][Full Text] [Related]
38. Selective augmentation of striatal functional connectivity following NMDA receptor antagonism: implications for psychosis.
Dandash O; Harrison BJ; Adapa R; Gaillard R; Giorlando F; Wood SJ; Fletcher PC; Fornito A
Neuropsychopharmacology; 2015 Feb; 40(3):622-31. PubMed ID: 25141922
[TBL] [Abstract][Full Text] [Related]
39. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.
Malhotra AK; Pinals DA; Adler CM; Elman I; Clifton A; Pickar D; Breier A
Neuropsychopharmacology; 1997 Sep; 17(3):141-50. PubMed ID: 9272481
[TBL] [Abstract][Full Text] [Related]
40. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors.
Bubeníková-Valesová V; Horácek J; Vrajová M; Höschl C
Neurosci Biobehav Rev; 2008 Jul; 32(5):1014-23. PubMed ID: 18471877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
